首页> 美国卫生研究院文献>British Medical Journal >First results of a randomized clinical trial of fast neutrons compared with X or gamma rays in treatment of advanced tumours of the head and neck. Report to the Medical Research Council.
【2h】

First results of a randomized clinical trial of fast neutrons compared with X or gamma rays in treatment of advanced tumours of the head and neck. Report to the Medical Research Council.

机译:快速中子与X射线或γ射线比较在头颈部晚期肿瘤治疗中的随机临床试验的初步结果。向医学研究理事会报告。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Results of the first randomized clinical trial to compare the effects of fast neutrons and those of x or gamma rays (photons) in treating patients with advanced tumours of the head and neck are reported. In 37 out of 52 patients treated with neutrons and 16 out of 50 treated with photons the local tumour completely regressed; the tumour later recurred in nine of the 16 photon patients but in none of the 37 neutron patients. The advantages to the neutron-treated patients were seen in tumours of well and poorly differentiated histology and in each site. Complications after treatment did not differ significantly between the groups. Despite these substantial differences in local control of the tumour there were no significant differences in mortality between the series. A detailed study of the effective doses and the response of tumours and normal tissue in each series indicated that the improved results from neutron therapy were due to differences in the biological quality of the beam and not to the rather higher average effective dose in the neutron series. To assess the long-term effects of neutron treatment patients in earlier stages of disease and with smaller tumours should be included in the next phase of the trial.
机译:据报道,第一个随机临床试验的结果比较了快中子和X射线或γ射线(光子)在治疗头颈部晚期肿瘤患者中的作用。在接受中子治疗的52位患者中,有37位接受了光子治疗;在接受光子治疗的50位患者中,有16位完全消退了局部肿瘤;该肿瘤随后在16名光子患者中的9名中复发,但在37名中子患者中均未复发。在组织学分化良好和分化差的肿瘤以及每个部位均可见中子治疗患者的优势。治疗后并发症在各组之间无显着差异。尽管在肿瘤局部控制方面存在这些实质性差异,但系列之间的死亡率没有显着差异。对每个系列的有效剂量以及肿瘤和正常组织的反应的详细研究表明,中子治疗的改善结果是由于电子束的生物学质量差异所致,而不是由于中子系列的平均有效剂量更高。为了评估中子治疗的长期效果,应将处于疾病早期且肿瘤较小的患者纳入试验的下一阶段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号